UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $210
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $190 to $210.
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $190 to $210.